{"id":"NCT02985541","sponsor":"Bayer","briefTitle":"Mirena Extension Trial","officialTitle":"Multi-center, Open-label, Uncontrolled Study to Assess Contraceptive Efficacy and Safety of Mirena During Extended Use Beyond 5 Years in Women 18 to 35 Years of Age Including a Subgroup Evaluation of Treatment Effect on Heavy Menstrual Bleeding","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-22","primaryCompletion":"2021-05-28","completion":"2021-05-28","firstPosted":"2016-12-07","resultsPosted":"2022-04-28","lastUpdate":"2022-04-28"},"enrollment":364,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Contraception"],"interventions":[{"type":"DRUG","name":"Levonorgestrel IUS (Mirena, BAY86-5028)","otherNames":[]}],"arms":[{"label":"Levonorgestrel IUS (Mirena, BAY86-5028)","type":"EXPERIMENTAL"}],"summary":"The study is performed to assess if Mirena is effective and safe as a birth control method beyond 5 years of use. Further the menstrual blood loss (in women that had Mirena inserted for the indication heavy menstrual bleeding \\[HMB\\]) and safety will be assessed.","primaryOutcome":{"measure":"Number of Pregnancies Per 100 Women Years (Pearl Index [PI]) Within Years 6 Thru 8 of Mirena Use","timeFrame":"Years 6 to 8 of Mirena use","effectByArm":[{"arm":"Levonorgestrel IUS (Mirena, BAY86-5028)","deltaMin":0.28,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":10},"locations":{"siteCount":49,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.bayer.com/"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":362},"commonTop":["Weight increased","Bacterial vaginosis","Urinary tract infection","Nasopharyngitis","Anxiety"]}}